RecruitingDravet Syndrome
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
Eligible age
2–17 yrs
Accepts
All genders
Locations
18 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome.
Sponsor: Stoke Therapeutics, Inc
Where it's recruiting
Arizona
Phoenix
Arkansas
Little Rock
California
Los Angeles · Orange · San Francisco
Colorado
Aurora
District of Columbia
Washington D.C.
Florida
Jacksonville · Miami · Orlando
Illinois
Chicago
Massachusetts
Boston
Michigan
Ann Arbor
Minnesota
Rochester
New York
New York · Rochester
North Carolina
Chapel Hill · Durham
Source: ClinicalTrials.gov · NCT06872125 · last updated 2026-08-24